NCI
Breast Pre-Malignancy Program

Presentation to the National Cancer Advisory Board

Dinah Singer, Ph.D.
Director, Division of Cancer Biology
February 6, 2007
Background:

- **Purpose:** Support breast cancer research and raise public awareness about the disease.

- **Allows U.S. Postal Service to sell a special issue stamp with a surcharge above the first-class postage rate (current rate 45 cents).**

- **Authorized by P.L. 105-41 in August 1997 and reauthorized through 2007 by P.L. 109-100.**
Stamp-Out Breast Cancer Stamp Act

- 70% of donated funds allocated to the National Cancer Institute, NIH
- 30% of donated funds allocated to the Department of Defense Breast Cancer Research Program
NCI Breast Cancer Research
Supported via the Fund

- As of FY 2006, NCI received a total of $35.2 million
- Funds have supported two programs:
  - Insight Awards to Stamp-Out Breast Cancer
    (Support of R21s- high risk research)
  - Breast Cancer Research Stamp Act Awards
    (Funding of R01 proposals focused exclusively on breast cancer that were outside the pay line)
- For FY 2007, NCI has $8.3 million from the Fund to support additional breast cancer research
Breast pre-malignancy research was identified as the target area for use of new Breast Cancer Stamp Act funds.

The NCI Breast Pre-Malignancy Program was established, consisting of 6 research components.

A Trans-NCI Steering Committee was formed to provide oversight and integration to the Program:
- All 5 extramural and both intramural Divisions and most Centers are represented.
NCI Breast Pre-Malignancy Program

Six Projects were Selected by the NCI Executive Committee For Support:

- Biology of Breast Pre-Malignancy (DCB)
- Molecular Epidemiology and Mammographic Density (DCEG)
- Evaluation of Decision-Making Approaches Used by Women Recruited to Chemoprevention Trials for Breast Cancer (DCP)
- Evaluation Strategies to Improve Accuracy of Mammography Interpretation with the Breast Cancer Surveillance Consortium Research Resources (DCCPS)
- MRI-Guided Therapy with Targeted SPIO Carbon Nanostructure – Supplement to a Breast Cancer SPORE (DCTD)
- Isolation, Propagation, Characterization, and Imaging of Breast Cancer Stem Cells to Improve Early Diagnosis and Therapy of Breast Cancer; and Development and Characterization of Affibody®-Based Bioconjugates for Molecular Imaging and Targeted Therapy of HER2-Positive Breast Cancers (CCR)
Isolation, Propagation, Characterization, and Imaging of Breast Cancer Stem Cells to Improve Early Diagnosis and Therapy of Breast Cancer

Barbara K. Vonderhaar, Ph.D.
Chief, Mammary Biology and Tumorigenesis Laboratory
Co-Chair Breast and Gynecologic Malignancies Faculty
Center for Cancer Research, NCI